Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
Altimmune (NASDAQ:ALT) has announced it will host an investor webcast on June 26, 2025, at 8:30 AM ET to present topline 24-week results from its IMPACT Phase 2b trial of pemvidutide in treating metabolic dysfunction-associated steatohepatitis (MASH). The conference call will feature remarks from Altimmune management and Dr. Mazen Noureddin, Professor of Medicine at Houston Methodist Hospital and Co-Chairman of the Board for Summit Clinical Research and Pinnacle Clinical Research.
The webcast will be available for replay on the company's Investor Relations website following the presentation. Participants can access the call by registering online to receive dial-in information.
Altimmune (NASDAQ:ALT) ha annunciato che terrà una webcast per gli investitori il 26 giugno 2025 alle 8:30 AM ET per presentare i risultati principali a 24 settimane del suo trial di Fase 2b IMPACT sul pemvidutide nel trattamento della steatoepatite associata a disfunzione metabolica (MASH). La conference call includerà interventi dal management di Altimmune e dal Dott. Mazen Noureddin, Professore di Medicina presso l'Houston Methodist Hospital e Co-Presidente del Consiglio di Summit Clinical Research e Pinnacle Clinical Research.
La webcast sarà disponibile in replica sul sito web delle Relazioni con gli Investitori della società dopo la presentazione. I partecipanti possono accedere alla chiamata registrandosi online per ricevere le informazioni di accesso.
Altimmune (NASDAQ:ALT) ha anunciado que realizará una webcast para inversores el 26 de junio de 2025 a las 8:30 AM ET para presentar los resultados principales a 24 semanas de su ensayo de Fase 2b IMPACT con pemvidutide en el tratamiento de la esteatohepatitis asociada a disfunción metabólica (MASH). La llamada de conferencia contará con intervenciones de la dirección de Altimmune y del Dr. Mazen Noureddin, Profesor de Medicina en el Houston Methodist Hospital y Copresidente del Consejo de Summit Clinical Research y Pinnacle Clinical Research.
La webcast estará disponible para reproducción en el sitio web de Relaciones con Inversores de la compañía tras la presentación. Los participantes pueden acceder a la llamada registrándose en línea para recibir la información de acceso.
Altimmune (NASDAQ:ALT)는 2025년 6월 26일 오전 8시 30분 ET에 투자자 웹캐스트를 개최하여 대사 기능 장애 관련 지방간염(MASH) 치료를 위한 pemvidutide의 IMPACT 2b상 임상시험 24주차 주요 결과를 발표할 예정입니다. 이번 컨퍼런스 콜에는 Altimmune 경영진과 휴스턴 메서디스트 병원 의학 교수이자 Summit Clinical Research 및 Pinnacle Clinical Research 이사회 공동 의장인 마젠 누레딘 박사가 참여합니다.
웹캐스트는 발표 후 회사 투자자 관계 웹사이트에서 다시보기로 제공됩니다. 참가자는 온라인 등록을 통해 전화 접속 정보를 받을 수 있습니다.
Altimmune (NASDAQ:ALT) a annoncé qu'elle organisera une webdiffusion pour les investisseurs le 26 juin 2025 à 8h30 ET afin de présenter les résultats principaux à 24 semaines de son essai de phase 2b IMPACT sur le pemvidutide dans le traitement de la stéato-hépatite associée à une dysfonction métabolique (MASH). La conférence téléphonique comprendra des interventions de la direction d'Altimmune ainsi que du Dr Mazen Noureddin, professeur de médecine à l'hôpital Houston Methodist et coprésident du conseil d'administration de Summit Clinical Research et Pinnacle Clinical Research.
La webdiffusion sera disponible en replay sur le site des relations investisseurs de la société après la présentation. Les participants peuvent accéder à l'appel en s'inscrivant en ligne pour recevoir les informations de connexion.
Altimmune (NASDAQ:ALT) hat angekündigt, am 26. Juni 2025 um 8:30 Uhr ET ein Investoren-Webcast abzuhalten, um die wichtigsten 24-Wochen-Ergebnisse seiner IMPACT Phase-2b-Studie mit Pemvidutid bei der Behandlung der metabolisch bedingten Steatohepatitis (MASH) vorzustellen. Die Telefonkonferenz wird Beiträge des Altimmune-Managements sowie von Dr. Mazen Noureddin, Professor für Medizin am Houston Methodist Hospital und Co-Vorsitzender des Vorstands von Summit Clinical Research und Pinnacle Clinical Research, enthalten.
Das Webcast wird nach der Präsentation auf der Investor-Relations-Website des Unternehmens als Wiedergabe verfügbar sein. Teilnehmer können sich online registrieren, um die Einwahlinformationen zu erhalten.
- None.
- None.
Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.
GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, will host an investor webcast on Thursday, June 26, 2025 at 8:30 am E.T. to present topline 24 week data from its IMPACT Phase 2b trial evaluating pemvidutide in the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH).
Conference Call Information
The Company will host a conference call and webcast at 8:30 am E.T. on June 26, 2025. The call will include remarks from Altimmune management and Dr. Mazen Noureddin, Professor of Medicine at the Houston Methodist Hospital and Co-Chairman of the Board for Summit Clinical Research and Pinnacle Clinical Research. Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company’s website at www.altimmune.com.
| Conference Call Details: | |
| Date: | Thursday, June 26, 2025 |
| Time: | 8:30 am Eastern Time |
| Webcast: | To listen, the conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors. |
| Dial-in: | To participate or dial-in, register here to receive the dial-in numbers and unique PIN to access the call. |
About the IMPACT Study
The IMPACT (NCT05989711) trial enrolled 212 patients with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes randomized 1:2:2 to receive either weekly subcutaneous pemvidutide at 1.2 mg and 1.8 mg doses or placebo for 24 weeks. Key efficacy endpoints were MASH resolution or fibrosis improvement at 24 weeks. Secondary endpoints included weight loss and non-invasive tests. Patients will receive a total of 48 weeks of treatment, and a final readout is anticipated in the fourth quarter of 2025.
About Pemvidutide
Pemvidutide is a novel, investigational, peptide-based 1:1 GLP-1/glucagon dual receptor agonist in development for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol-associated Liver Disease (ALD). Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated statistically significant MASH resolution and liver fibrosis improvement, compelling weight loss with class-leading lean mass preservation, and robust reductions in liver fat content, triglycerides, LDL cholesterol and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide completed the MOMENTUM Phase 2 obesity trial in 2024 and the ongoing IMPACT Phase 2b MASH trial, for which data will be reported on tomorrow’s call. IND applications in AUD and ALD have received FDA clearance, with a Phase 2 trial in AUD underway and a Phase 2 trial in ALD scheduled to commence in Q3 2025.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, AUD and ALD. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Forward-Looking Statement
Any statements made in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, the timing of key milestones for our clinical assets, and the prospects for the utility of regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K and our other filings with the SEC, which are available at www.sec.gov.
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Jake Robison
Inizio Evoke, Biotech
Phone: 619-849-5383
jake.robison@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Altimmune (ALT) announce the IMPACT Phase 2b trial results for pemvidutide?
What is the purpose of Altimmune's IMPACT Phase 2b trial?
Who will be presenting at Altimmune's investor webcast?
How can investors access Altimmune's pemvidutide trial results webcast?
